https://www.selleckchem.com/pr....oducts/imlunestrant.
s (pulmonary nodules). Non-valvular atrial fibrillation (NVAF) is often accompanied by multiple comorbid conditions, which increase the associated risks and complexity of patient management. This study evaluated the risk of stroke/systemic embolism (SE) and major bleeding (M among multimorbid patients with NVAF who were prescribed non-vitaminK antagonist oral anticoagulants (NOACs) or warfarin. A retrospective study of patients with NVAF and high multimorbidity who initiated apixaban, dabigatran, rivaroxaban, or warfarin from 1Ja